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PURPOSE:This study aims to investigatewhether theuptakeof 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-
acetamide ([18F]EF5) and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is associated with a hypoxia-driven adverse
phenotype in head and neck squamous cell carcinoma cell lines and tumor xenografts. METHODS: Xenografts were
imaged in vivo, and tumor sectionswere stained for hypoxia-inducible factor 1α (Hif-1α), carbonic anhydrase IX (CA IX),
and glucose transporter 1 (Glut-1). Tracer uptakes and the expression of Hif-1αwere determined in cell lines under 1%
hypoxia. RESULTS: High [18F]EF5 uptake was seen in xenografts expressing high levels of CA IX, Glut-1, and Hif-1α,
whereas low [18F]EF5 uptake was detected in xenografts expressing low amounts of CA IX and Hif-1α. The uptake of
[18F]EF5 between cell lines varied extensively under normoxic conditions. A clear correlation was found between the
expression ofHif-1α and the uptake of [18F]FDGduringhypoxia.CONCLUSIONS:TheUT-SCCcell lines studied differed
with respect to their hypoxic phenotypes, and these variationswere detectablewith [18F]EF5. Acute hypoxia increases
[18F]FDG uptake in vitro, whereas a high [18F]EF5 uptake reflects a more complex phenotype associated with hypoxia
and an aggressive growth pattern.
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Imaging of tumor hypoxia using 2-nitroimidazoles has increased during
recent years. For a number of cancers, including head and neck
squamous cell carcinomas (HNSCCs), radiotherapy (RT) may fail due
to the presence of tumor hypoxia [1]. However, before imaging of
hypoxic tumors can be employed for hypoxia-directed treatment
strategies, the biologic significance of imaging data needs to be validated
[2]. This molecular information may be useful for planning RT, as well
as in drug development. Image-guided radiotherapy is routinely
implemented to reduce safety margins associated with delineation of
clinical target volume, but it is also necessary to irradiate biologically
relevant subvolumes within the tumor [3]. In view of the heterogeneity
of tumor tissue, it is hoped that this targeted irradiation can improve the
survival prospects of patients with cancer.The microenvironmental homeostasis in tumors is disrupted, and
several metabolic changes, such as gradients of oxygen, glucose,
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tumor cells must survive in this hypoxic environment and the acidic
surroundings, both of which are currently considered as hallmarks of
cancer [5]. Hypoxic cells are able to adapt to the demanding
environments by activating hypoxia-inducible factor 1 (Hif-1), a
heterodimer consisting of α and β-subunits [6,7]. Hif-1 activates the
transcription of many genes, for example, those involved in
angiogenesis, glycolysis [e.g., glucose transporters (GLUTs)], pH
maintenance [e.g., carbonic anhydrases (CAs)], and proliferation [8,9].
In summary, the activation of Hif-1 helps cells to adapt to an
environment with a low-oxygen level. CAs are a family of proteins
that catalyze reversibly the hydration of the carbon dioxide to
carbonic acid, and thus help cells to survive in an acidic environment
[10]. CA isoform 9 (CA IX) is found in many aggressive tumors,
including HNSCC, and has been associated with poor treatment
outcomes [11,12]. The acidic microenvironment can also trigger
nonhypoxic cells to use glycolysis as their primary energy source [13].
Glucose is transported into cells by GLUTs, which are overexpressed
in many cancers, including HNSCC [14]. Higher Glut-1 expression
has been shown to correlate with a poorer survival in many cancers
[14,15], although contradictory results on the correlation between
Glut-1 expression and the uptake of 2-deoxy-2-[18F]fluoro-D-glucose
([18F]FDG) have been reported [16].
Hypoxia imaging with positron emission tomography (PET) is
usually based on 18F-labeled 2-nitroimidazole compounds [17]. We
have earlier evaluated the hypoxia tracer 2-(2-nitro-1H-imidazol-1-yl)-
N-(2,2,3,3,3-pentafluoropropyl)-acetamide ([18F]EF5) in patients with
HNSCC [18]. In this study, the uptake of [18F]EF5 and [18F]FDG
into primary tumors and cervical lymph node metastases was found to
be heterogeneous. Previous studies using unlabeled EF5 have described
a correlation between hypoxia and tumor aggressiveness [19,20].
Understanding the relationship between oxygen and glucose metabo-
lism is crucial for the planning of hypoxia-directed therapies, such as
biologically guided RT. Therefore, these findings encouraged us to
investigate in detail whether a certain molecular profile might affect
[18F]EF5 and [18F]FDG uptake in HNSCC.
We studied the in vivo uptake of [18F]EF5 and [18F]FDG
in xenografts from UT-SCC cell lines. We also evaluated the
in vitro accumulation of these tracers in the same cell lines.
Finally, we investigated the association between these PET tracers
and biologic markers commonly considered to be related to [18F]
EF5 and [18F]FDG uptake or to the tumorigenesis of HNSCC.Table 1. Origin of the UT-SCC Cell Lines.
Cell Line Primary Tumor
Location Sex TNM Grade
UT-SCC-8 Supraglottic larynx M T2N0M0 G1
UT-SCC-25 Mobile tongue M T2N0M0 G1
UT-SCC-34 Supraglottic larynx M T4N0M0 G1
UT-SCC-74A Mobile tongue M T3N1M0 G1-G2Materials and Methods
[ 18F]EF5 and [18F]FDG Production
[18F]EF5 was synthesized from 2-(2-nitro-1H-imidazol-1-yl)-N-
(2,3,3-trifluoroallyl)-acetamide using high-specific activity [18F]F2
([18F]fluorine gas) as the labeling reagent [21]. The specific activity of
[18F]EF5, decay corrected to the end of synthesis, exceeded 3.7 GBq/
μmol. Radiochemical purity was higher than 98.5% in every
production batch.
[18F]FDG was synthesized from mannosyl triflate using a
nucleophilic method. The radiochemical purity exceeded 95% in
every production batch.
Cell Lines and Cell Culture
Four primary cell lines (Table 1) derived from human HNSCC
and originating from the UT-SCC collection were kindly provided byProf Reidar Grénman. Cells were routinely cultured in Dulbecco's
modified Eagle's medium (Gibco®, Thermo Scientific, Waltham,
MA, USA) containing L-glutamine (Gibco), nonessential amino acids
(Gibco), streptomycin, penicillin (Gibco), and 10% FBS (Gibco) at
37°C in a humidified atmosphere containing 5% CO2.
Animals and Tumor Models
Male nude mice (Athymic nu/nu; Harlan Laboratories, Horst,
The Netherlands), weighing 33.1 (29.0-37.1) g, were used to
establish xenografts from UT-SCC-8, UT-SCC-25, UT-SCC-34,
and UT-SCC-74A HNSCC cell lines. Mice were irradiated with 4 Gy
(3 Gy/min) 1 day before tumor transplantation to reduce their
immunity. Depending on the cell line, 1 to 10 × 106 cells were
subcutaneously injected into the flank of each mouse. Throughout
this study, cell line passage numbers were kept as low as possible (p6-
p40). Mice were maintained in individually ventilated animal cages
under controlled pathogen-free environmental conditions (21°C,
humidity = 55 ± 5%, and lights on from 6:00 A.M. to 6:00 P.M.)
with free access to water and standard food. Animals were observed on
daily basis, and tumor sizes were measured weekly (V = (π/6) × a × c × b).
The experimental procedures were reviewed by the local Ethics
Committee on Animal Experimentation at the University of Turku
and approved by the Provincial State Office of Western Finland.
In vivo Imaging of Xenografts
Mice (n = 3 per cell line) bearing tumors with an average size of 406
(105-685) mm3 were anesthetized with 2.5% isoflurane, and body
temperature was maintained using a heating pad. Following a transmission
scan for attenuation correction using the computer thomography (CT)
modality, an emission scan was acquired in three-dimensional list mode
(Inveon; Siemens Medical Solutions, Knoxville, TN, USA).
Mice were injected with 11.6 (9.1-14.0) MBq of [18F]EF5 or 12.1
(10.7-13.3) MBq of [18F]FDG into a tail vein on consecutive days.
Dynamic 80-minute–long scans were acquired. Sinograms were
framed into 25 frames (6 × 10 seconds, 4 × 15 seconds, 2 × 30
seconds, 2 × 120 seconds, 1 × 180 seconds, 6 × 300 seconds, and 4 ×
600 seconds) and reconstructed with an ordered subset expectation
maximation (OSEM) two-dimensional iterative algorithm. Images were
summed from 60 to 80 minutes, and volumes of interest were drawn
over whole tumors with Inveon Research Workplace image analysis
software 4.1 (Siemens Medical Solutions), using the CT template as an
anatomic reference. Radioactivity uptake was calculated as the
percentage of injected dose per gram tissue (%ID/g) in whole tumor.
Expression of CA IX, Glut-1, and Hif-1α in Xenografts
After PET/CT scans, mice were killed, tumors were collected, and
paraffin-embedded tumor sections were stained with antibodies raised
against CA IX (ab15086; Abcam, Cambridge, UK, 1:8000), Glut-1
(GT12-A; Immune Diagnostics and Research, Hämeenlinna, Finland,
1:1000), and Hif-1α (610959; BD Transduction Laboratories,
Franklin Lakes, NJ, USA, 1:100). Immunostaining was performed
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Hif-1α were visually analyzed from 10 different areas in each tumor
section using a ×20 microscope objective. The percentage of positively
stained tumor cells was counted, and staining intensity was described as
weak (1),moderate (2), or strong (3). Each tumor was scored (range = 0-
300) by multiplying the average intensity value by the average
percentage of positively stained cells. Analyses were performed
independently by two investigators (J.S. and K.K.).
In vitro Uptake of Tracers in Cell Lines
Digital autoradiography was used to measure the uptake of [18F]EF5
and [18F]FDG in cell lines grown on eight-well chamber slides (Nunc™,
Thermo Scientific,Waltham,MA, USA) under normoxia and different
time periods of hypoxia (1% O2). Four days before tracer incubation,
cells were plated onto chamber slides in duplicate (two wells per cell
line) and cultured under normal culturing conditions. Medium was
changed on the third day. Cells were seeded at various densities
according to their growth rates to ensure that there would be equal
amount of cells at the time of tracer incubation. On day 4, one chamber
slide per time point was transferred to a hypoxia workstation (Invivo2;
Ruskinn Technology Ltd, Pencoed, United Kingdom) at 24, 12, 6,
3, and 1 hour before the end of tracer incubation time. Chambers
were removed, and slides were washed with phosphate-buffered saline
before being incubated with [18F]EF5 or [18F]FDG for 60 or 30
minutes, respectively, in 50 kBq/ml Dulbecco's modified Eagle's
medium ([18F]EF5) or physiological saline ([18F]FDG) under hypoxia.
The workstation and all solutions used were stabilized in 1%O2 before
the experiment. Control cells were incubated with tracers under normal
culture conditions (normoxia, 0 hour). Cells were then washed with
phosphate-buffered saline and fixed in 4% paraformaldehyde for 10
minutes at room temperature. Air-dried slides were exposed with an
imaging plate (BAS-TR2025; Fuji Photo Film Co, Tokyo, Japan) for 4
hours before scanning with the Fuji Analyzer FLA-5100.Figure 1. (A) [18F]EF5 and [18F]FDGuptake (summedat 60-80 minutes pos
(n=3), andUT-SCC-74A (n=3) cell lines.UT-SCC-25cells did not formxeno
seen in UT-SCC-8 xenografts compared to UT-SCC-34 xenografts. (B) Tim
show that equilibriumofboth tracerswasachievedat 20minutesp.i. (C)Re
xenografts. Tumors are marked with dotted lines and arrows.Images were analyzed for count density [photostimulated lumines-
cence (PSL) per unit area] with a computerized image analysis program
(AIDA Image Analyzer version 4.22; Raytest Isotopenmessgeräte,
Straubenhardt, Germany). A square-sized region of interest was drawn
over each chamber containing cultured cells, and the background was
subtracted from the image data. Data were normalized to the total
amount of radioactivity used in each experiment.
Hif-1α Expression in Cell Lines
Cells were cultured in six-well plates (Nunc) in a hypoxic workstation
(Invivo2; Ruskinn Technology Ltd) under 1% O2 at 37°C for 1, 3, 6,
12, and 24 hours. Control cells were cultured in 21% O2 at 37°C
(normoxia, 0 hour). Cells were harvested by adding 200 μl of sodium
dodecyl sulfate (SDS)–Triton lysis buffer [50 mM Tris (pH 7.5),
150 mMNaCl, 0.5% Triton X-100 (TX-100), 5% glycerol, 1% SDS,
and a complete protease inhibitor tablet]. Total cellular protein
concentrations were determined using the bicinchoninic acid assay
method (BCA Protein Assay Kit; Pierce™, Thermo Scientific,Waltham,
MA, USA) before addition of SDS buffer. Equal amounts of protein
were separated on a 10% SDS–polyacrylamide gel electrophoresis and
blotted onto a polyvinylidene fluoride (PVDF) membrane (Bio-Rad
Laboratories, Hercules, CA, USA). Proteins were detected by Western
blot analysis and enhanced chemiluminescence with Hif-1α antibody
(610959; BD Transduction Laboratories, 1:3000). β-Actin was used as
a loading control (Ac-74; Sigma-Aldrich, St. Louis, MO, USA 1:3000).
Statistics
Descriptive statistics for the data are presented as arithmetic means and
range. Mean levels of [18F]EF5 and [18F]FDG (tumor uptake),
membranous CA IX, membranous Glut-1, and nuclear Hif-1α
scores were compared between groups (UT-SCC-8, UT-SCC-34, and
UT-SCC-74A) with one-way analysis of variance (ANOVA). Likewise,
mean levels of [18F]EF5 (in vitro uptake) were compared between UT-t injection (p.i.)) in xenografts induced fromUT-SCC-8 (n=3), UT-SCC-34
grafts. A trend toward significantly lower (P=.091) [18F]EF5uptakewas
e activity curves for [18F]EF5 (black line) and [18F]FDG (grey line) uptake
presentative axial imagesshow tumoruptakeof [18F]EF5and [18F]FDG in
326 Imaging Hypoxic Phenotype in HNSCC Silén et al. Translational Oncology Vol. 7, No. 3, 2014SCC-8, UT-SCC-25, UT-SCC-34, and UT-SCC-74A. In addition,
pairwise comparison between groups was performed with Tukey test.
Pearson correlation coefficient was calculated between [18F]FDGuptake
andHif-1α expression for each group separately. All tests were performed
as two sided with a 0.05 significance level. In addition, P values less
than .10 were reported as a trend toward significance. The analyses
were done with SAS System (version 9.3 for Windows) (SAS Institute,
Cary, NC, USA).
Results
Uptake of [ 18F]EF5 and [18F]FDG in Xenografts
Xenografts derived from UT-SCC-25 cells did not grow in
nude mice. The uptake of [ 18F]EF5 and [ 18F]FDG in
individual xenografts induced from UT-SCC-8, UT-SCC-34,
and UT-SCC-74A cell lines is shown in Figure 1A. The uptake
of both tracers reached equilibrium in tumors after 20 minutes
(Figure 1B). Representative PET images of [18F]EF5 and [18F]FDG
uptake are shown in Figure 1C. The uptake of [18F]EF5 in UT-SCC-8
tumors was 0.87 (0.68-0.99) %ID/g and showed a trend toward
a significantly lower (P = .091) uptake than the [18F]EF5 uptake
in UT-SCC-34 tumors [2.2 (1.4-2.7) % ID/g]. The uptake in
UT-SCC-74A tumors was also higher [1.9 (1.1-2.7)%ID/g] than in
UT-SCC-8 xenografts, although not statistically significantly (P = .194).
The uptake of [18F]FDG in UT-SCC-34 and UT-SCC-74A xenografts
was higher than in UT-SCC-8 xenografts [2.2 (1.7-3.1)%ID/g versus 2.1
(1.4-2.7) %ID/g versus 1.5 (1.3-1.6) %ID/g, respectively], even though
the difference did not achieve statistical significance.Figure 2. (A) Representative images of CA IX, Glut-1, and Hif-1α exp
intensity) for CA IX, Glut-1, and Hif-1α expression in UT-SCC-8 (n =
significantly lower (P= .039) membranous CA IX expression was dete
The expression of membranous Glut-1 did not significantly differ betw
(P = .012) in UT-SCC-74A, whereas a trend toward a lower (P = .
xenografts. Scale bar, 100 μm.Expression of CA IX, Glut-1, and Hif-1α in Xenografts
Representative images and mean scores of CA IX, Glut-1, and Hif-1α
expression in xenografts of UT-SCC-8, UT-SCC-34, and UT-SCC-74A
cell lines are illustrated in Figure 2. Percentages of positive stained tumor
cells and staining intensities of individual UT-SCC xenografts are listed in
Table 2. One-way ANOVA revealed differences between the cell lines
for CA IX andHif-1α expression (P = .046 andP = .014, respectively),
whereas there were no significant differences between the cell lines in the
levels of Glut-1 expression (P = .147).
All xenografts exhibited membranous CA IX expression. In UT-
SCC-8 xenografts, the mean CA IX–positive tumor cells was below
10% (Table 2). The highest CA IX scores were observed in UT-SCC-
34 tumors (Figure 2B), which exhibited weak to strong staining in
more than 50% of tumor cells (Table 2). In UT-SCC-74A
xenografts, below 30% of tumor cells were positive for membranous
CA IX (Table 2). However, UT-SCC-74A xenografts expressed
more extensive variation in the proportion and staining intensity of
CA IX–positive tumor cells. Total scores for CA IX in UT-SCC-8,
UT-SCC-34, and UT-SCC-74A were 9 (3-13), 92 (66-111), and 50
(16-105), respectively (Figure 2B). Pairwise comparison (Tukey)
between UT-SCC-8, UT-SCC-34, and UT-SCC-74A xenografts
revealed significantly (P = .039) higher CA IX scores in UT-SCC-34
compared to UT-SCC-8 xenografts (Figure 2B).
All xenografts were positive for membranous Glut-1. More than
60% of cells in UT-SCC-8 xenografts were Glut-1 positive, with
mostly moderate to strong staining intensities. In UT-SCC-34
xenografts, 65% of the cancer cells were Glut-1 positive, exhibiting
divergent staining intensities but equal distribution within theression in UT-SCC xenografts. (B) Scores (positive cells × staining
3), UT-SCC-34 (n = 3), and UT-SCC-74A (n = 3) xenografts. A
cted in UT-SCC-8 xenografts compared with UT-SCC-34 xenografts.
een cell lines. Nuclear expression of Hif-1α was significantly lower
082) expression was seen in UT-SCC-8, compared to UT-SCC-34
Table 2. Percentage of Positive Stained Tumor Cells, Staining Intensities and Total Scores of CA




Positive Tumor Cell (%) Score * P Value †
Intensity
1=weak 2=moderate 3=strong
CA IX UT-SCC-8 8 7 1 0 9
UT-SCC-34 52 22 21 9 92 .046
UT-SCC-74A 27 11 12 5 50
Glut-1 UT-SCC-8 63 10 32 21 137
UT-SCC-34 65 20 28 18 128 .147
UT-SCC-74A 30 7 11 12 65
Hif-1α UT-SCC-8 20 9 9 2 33
UT-SCC-34 44 20 17 7 75 .014
UT-SCC-74A 5 3 1 1 8
* Scores were calculated by multiplying the percentage of positive stained tumor cells with corresponding
intensity value (1-3) and summing the values.
† P values from one-way ANOVA.
Figure 3. In vitro uptake of [18F]EF5 in UT-SCC-8, UT-SCC-25, UT-SCC-
34, andUT-SCC-74Acell lines. Cellswere grownunder normoxia (N) or
for increasing durations (1, 3, 6, 12, and 24 hours) of hypoxia (1%O2).
Significantly different (P b .0001) [18F]EF5 uptake was seen between
the cell lines under N, except between UT-SCC-34 and UT-SCC-74A,
which showed similarly high uptake. Values are from three repeated
experiments. PSL, photostimulated luminescence.
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strong in UT-SCC-74A, although the overall proportion of positive
cells was only 30% (Table 2). Total scores for Glut-1 in UT-SCC-8,
UT-SCC-34, and UT-SCC-74A were 137 (87-190), 128 (101-162),
and 65 (29-105), respectively (Figure 2B). No significant differences
in Glut-1 scores were detected between the UT-SCC xenografts.
UT-SCC-34 xenografts exhibited strongest nuclear Hif-1α expres-
sion (Figure 2A). In these xenografts, more than 40% of tumor cells
were positive for nuclear Hif-1α, compared with only 5% of positive
tumor cells in UT-SCC-74A xenografts and 20% in UT-SCC-8
xenografts (Table 2). Total scores for Hif-1α in UT-SCC-8, UT-SCC-
34, and UT-SCC-74A were 33 (15-53), 75 (55-93), and 8 (0-24),
respectively (Figure 2B). Pairwise comparison between UT-SCC-8,
UT-SCC-34, and UT-SCC-74A xenografts revealed significantly (P =
.012) higher Hif-1α scores in UT-SCC-34 compared with UT-SCC-
74A xenografts (Figure 2B), whereas the lower scores seen in UT-SCC-
8 xenografts reached only marginal significance (P = .082).
Cell Line–Specific Uptake of [ 18F]EF5
UT-SCC-34 and UT-SCC-74A cells exhibited the highest [18F]
EF5 uptake, whereas low uptake was seen in UT-SCC-25 cells
(Figure 3). After 1 hour of exposure to hypoxia, [18F]EF5 uptake
increased slightly in all UT-SCC cell lines. However, this uptake
declined over time toward the levels detected in the normoxic
conditions (Figure 3). One exception to this pattern was detected in
UT-SCC-74A cells in which a higher [18F]EF5 uptake was seen at
24 hours after exposure to hypoxia in comparison to normoxic
conditions. However, significantly different (P b .0001) [18F]EF5
uptake was already seen between the cell lines under normoxia,
except between UT-SCC-34 and UT-SCC-74A, which showed
similar high uptake.
Association Between [18F]FDGUptake and HIF-1α Expression
In general, the hypoxic environment increased the uptake of [18F]
FDG in UT-SCC cell lines (Figure 4A). The uptake of [18F]FDG
observed in UT-SCC-34 cells remained rather stable between 1 to
24 hours of hypoxia exposure. UT-SCC-8, UT-SCC-25, and UT-
SCC-74A exhibited a more variable [18F]FDG uptake; UT-SCC-8
increased over time until 6 hours, and UT-SCC-74A increased in a
dual-phase manner over time being greatest after 24 hours of
hypoxia. UT-SCC-25 cells exhibited the least [18F]FDG uptake of
the four cell lines studied.Hif-1α expression was detected during hypoxia, whereas under
normoxic conditions, Hif-1α expression was absent or weak
(Figure 4A). The expression of Hif-1α in the UT-SCC-74A cell line
deviated from the commonly observed expression pattern by exhibiting
the strongest expression after 24 hours instead of at 3 to 6 hours of
hypoxia. TheHif-1α expression correlated strongly with the [18F]FDG
uptake in the UT-SCC-74A cell line (r = 0.984; P = .0004). This
correlation was slightly weaker in UT-SCC-34 (r = 0.801; P = .0554),
UT-SCC-25 (r = 0.763; P = .0774), and UT-SCC-8 (r = 0.721; P =
.1057) cell lines (Figure 4B).
Discussion
Our aim in this study was to investigate whether a certain molecular
profile might affect [18F]EF5 and [18F]FDG uptake in HNSCC. The
main finding of our study is that [18F]EF5 uptake appears to be related
to a hypoxia-driven adverse phenotype. The highest [18F]EF5 uptake
was seen in UT-SCC-34 xenografts (Figure 1), which also expressed
high amounts of CA IX, Glut-1, and Hif-1α (Figure 2 and Table 2).
Moreover, much lower levels of [18F]EF5 uptake and CA IX and Hif-
1α expression were detected inUT-SCC-8 xenografts.We consider this
difference (P = .091) in [18F]EF5 uptake as a trend toward significance
in this limited sample number study. Compared to UT-SCC-8
xenografts, a higher, although not statistically significantly (P = .194),
uptake of [18F]EF5 was also detected in UT-SCC-74A xenografts. The
expression of CA IX was similarly higher in UT-SCC-74A xenografts,
whereas the expression of Hif-1α was significantly (P = .012) lower
compared with UT-SCC-34 xenografts.
CA IX is considered as a promising endogenous hypoxia-related
marker, and a significant but weak correlation has been reported
between CA IX staining and the distribution of the exogenous
hypoxic cell marker pimonidazole [22]. However, also, other
microenvironmental factors, such as pH homeostasis, affect the
expression of CA IX [23]. In a number of studies, CA IX has been
shown to be associated with a poorer locoregional control, overall
survival, and aggressive phenotype [24,25] Our finding that [18F]EF5
uptake, in addition to hypoxia, also reflects an adverse phenotype is
further supported by previous studies depicting a relationship
between unlabeled EF5 binding and tumor aggressiveness [19,20].
Figure 4. (A) In vitro uptake of [18F]FDG in UT-SCC-8, UT-SCC-25, UT-SCC-34, and UT-SCC-74A cell lines. Cells were grown under normoxia
(N) or for increasing durations (1, 3, 6, 12, and 24 hours) of hypoxia (1% O2). Hypoxia exposure increased the [
18F]FDG uptake in all
the studied UT-SCC cell lines. This uptake correlated with the Hif-1α expression. (B) The strongest correlation was found with UT-SCC74A
(r= 0.984), whereas a slightly weaker correlation was observed in UT-SCC-34 (r= 0.801), UT-SCC-25 (r= 0.763), and UT-SCC-8 (r= 0.721)
cell lines. Values are from three repeated experiments, except for normoxia (n = 2) and the UT-SCC-25 cell line (n = 1). PSL,
photostimulated luminescence.
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expression pattern of Hif-1α in UT-SCC-34 xenografts (Figure 2 and
Table 2) compared to UT-SCC-8, whereas the Hif-1α expression was
significantly lower in UT-SCC-74A xenografts (P = .012). In other
words, we did not observe any relationship between Hif-1α expression
and the uptake of [18F]EF5 (Figure 1).Our results are in line with earlier
studies reporting a limited, or nonexisting, colocalization of Hif-1α with
pimonidazole [26] and [18F]FMISO ([18F]fluoromisonidazole) [27].
Vucovic et al. [28] described a significant correlation between Hif-1α
expression and EF5 staining in cervical cancer xenografts. However, the
percentages of Hif-1α–positive cells staining for EF5 and vice versa
ranged between 10% to 20%, pointing to a rather low association
between these two markers. Moreover, declines in Hif-1α levels and
Hif-1 activity in the later phase of tumorigenesis have been reported by
Lehmann et al. [27].
In comparison to UT-SCC-8 xenografts, the uptake of [18F]FDG
was also higher, although not statistically significantly, in UT-SCC-
34 and UT-SCC-74A xenografts (Figure 1). This finding further
supports our conclusion that the phenotype of UT-SCC-34 and UT-
SCC-74A xenografts is more aggressive. Membranous Glut-1
expression was detected in all three UT-SCC xenografts. The
expression of Glut-1 did not relate to the uptake of [18F]FDG or
[18F]EF5. The highest expression was seen in UT-SCC-8 and UT-
SCC-34 xenografts, whereas the lowest expression was detected inUT-SCC-74A xenografts (Figure 2 and Table 2). Although tumors
frequently overexpress Glut-1, the cellular uptake of [18F]FDG is not
exclusively attributable to Glut-1 [16], which probably explains the
previous contradictory studies on the relationship between Glut-1
and [18F]FDG.
To further evaluate phenotype differences detected in the
xenografts in vivo, we determined the uptake of [18F]EF5 and
[18F]FDG in the cell lines in vitro. Cells were grown under normoxia
and for 1, 3, 6, 12, and 24 hours of 1% of oxygen (Figures 3 and 4).
These experiments confirmed the existence of phenotypic differences
detected in xenografts. The lowest uptake of both tracers was found in
UT-SCC-25 cells, which did not form xenografts in nude mice. The
greatest uptake was detected in UT-SCC-34 and UT-SCC-74A cells.
The uptake of [18F]EF5 increased after exposure to 1% of oxygen,
but interestingly, we observed differences between the cell lines in the
[18F]EF5 uptake already at normoxic conditions (Figure 3). This
finding indicates that the studied cell lines express different hypoxia-
driven adverse phenotypes that might influence their behavior, even
without the presence of a hypoxic environment. There might also be
variation in the activity of one-electron reductases required for
activation of 2-nitroimidazoles in cells. Whether there is a relationship
between these reductases and hypoxia-driven adverse phenotypes
remains to be clarified. Recently, [18F]EF5 was shown to be activated
by the same reductases as CEN-209 (a tirapazamine analog) in
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both hypoxia and reductase expression in tumors [29]. The impact of
hypoxia as a function of time affected the uptake of [18F]FDG to a
greater extent than [18F]EF5. The uptake of [18F]FDG clearly
increased after 1 hour of hypoxia exposure, typically being highest at 3
to 6 hours. UT-SCC-74A cells differed in this respect by displaying
the highest uptake after 24 hours of hypoxia (Figure 4).
To evaluate the ability of cell lines to adapt to a stressful hypoxic
environment, we also determined the expression of Hif-1α as a
function of time (Figure 4B). We found an extensive variation in its
expression level among the four cell lines, which furthermore correlated
with the uptake of [18F]FDG. This correlation most probably reflects
the metabolic adaptation of cells to hypoxia in vitro, which one could
speculate is regulated by the activation of Hif-1. The fact that hypoxia
induces anaerobic glycolysis and therefore the increases in [18F]FDG
uptake have been shown previously [30,31], although there are also
contradictory results as reported byBusk et al. [32]. The lack of response
reported in this study might be a result of contact-inhibited cells. We
observed that it is important to seed cells at correct densities to achieve
proliferative active cells during the time of tracer incubation. Contact-
inhibited cells, or cells grown at a low density, did not increase their
[18F]FDG uptake in 1% O2 (data not shown).
To summarize our observations, we found low uptake of [18F]EF5
and [18F]FDG in the UT-SCC-25 cell line, which was unable to
form xenografts. Low tracer uptakes were also detected in UT-SCC-8
cells and corresponding xenografts that expressed low amounts of CA
IX and Hif-1α. In contrast, UT-SCC-34 cells and xenografts
exhibited high levels of [18F]EF5 and [18F]FDG uptake in addition
to intense expression of CA IX, Glut-1, and Hif-1α. A more
heterogeneous pattern of both uptake of tracers and expression of CA
IX and Glut-1 was detected in UT-SCC-74A cells and xenografts.
Conclusion
In conclusion, our results demonstrate that the low-passage UT-SCC cell
lines evaluated in this study differ in their glycolytic and hypoxic
phenotypes. Importantly, these in vitro phenotypic differences can be
imaged in vivo and may thus be clinically evaluable using PET. Overall,
our results suggest that [18F]EF5 accumulation in HNSCC not only
reflects hypoxia but also is related to an adverse phenotype. [18F]FDG
uptake, in turn, may be sensitive to acute changes in oxygenation as
suggested by rapid response of expression ofHIF-1α to hypoxia in vitro.
The hypoxia tracer [18F]EF5 might be useful for the detection of hypoxic
and more aggressive HNSCC tumors, and thus, it could assist in planning
of hypoxia-directed therapies. The biologic genotype behind the
phenotypes reported in this study will need to be evaluated in greater detail.
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